CADL at a glance
Candel Therapeutics, Inc. (CADL, SEC CIK 1841387) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 10, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Candel Therapeutics, Inc. (CADL) shares worth $265.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Tak Paul Peter on September 11, 2026 of 59,379 shares at $10.46 per share.
- In the last 90 days, CADL insiders reported 0 open-market purchases ($0) and 3 open-market sales ($3.2M) on Form 4, a net sale of $3.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$3.2M
- 13F holders
- 24 funds
- $265.3M · +1 vs prior quarter
- Latest 8-K
- Sep 10, 2026
- Item 7.01 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Capital deployment: $85.9M net proceeds from December 2024 follow-on offering
- Outlook: anticipated aglatimagene BLA submission in Q4 2026 and linoserpaturev data expected in Q4 2026
Risk Factors
- No material-change comparison provided; risk section contains carried-forward risks rather than quarter-specific additions
- Funding runway into first quarter of 2028, with $201.6 million cash and $47.8 million six-month net loss
- Trinity debt facility up to $130.0 million, including $50.0 million outstanding, with covenant breaches potentially accelerating repayment
- No approved products or product-sale revenue, leaving commercialization dependent on clinical success and regulatory approvals
- Variable-rate debt exposed to higher interest costs, potentially reducing liquidity and increasing cash outflows
AI summary of the CADL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Martine Zimmermann, PharmD appointed to Candel Therapeutics’ Board of Directors
- Board addition may strengthen pharmaceutical development and commercialization expertise
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 10 to 11 directors; Martine Zimmermann appointed independent Class III director through 2027 annual meeting
- Regulatory expertise spanning FDA, EMA and Japanese authorities strengthens oversight of drug-development and approval strategy
Item EX-99.1: Item EX-99.1
- Martine Zimmermann appointed to Candel’s Board effective September 8, 2026
- More than 30 years of regulatory and quality experience strengthens oversight ahead of planned BLA submission
Item 7.01: Regulation FD Disclosure
- Investor presentation furnished under Regulation FD for use in discussions with investors and analysts
- Presentation likely provides current company messaging, pipeline context, and corporate updates
Item EX-99.1: Item EX-99.1
- September 2026 corporate presentation highlights positive Phase 3 prostate-cancer data for aglatimagene, supporting potential BLA filing in 2026
- Phase 3 trial enrolled 745 patients and achieved disease-free survival endpoint with 30% recurrence-risk reduction
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the financial results
Item EX-99.1: Item EX-99.1
- Q2 2026 R&D rose to $19.8M from $7.0M, reflecting accelerated prostate-cancer development and manufacturing investment
- Net loss widened to $38.9M from $4.8M, including $12.2M expense from warrant-liability revaluation
AI summaries of CADL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CADL
Don't miss the next CADL filing
- Alerts as it files. A push when CADL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CADL, by share count.
- Ask anything. An AI agent that reads every CADL filing and answers with sources.
CADL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Manning Paul B | A | Sep 30, 2026 | 2,189 | $8.68 |
| PAPA JOSEPH C | A | Sep 30, 2026 | 1,325 | $8.68 |
| Loggia Nicoletta | A | Sep 30, 2026 | 380 | $8.68 |
| Tak Paul Peter | Sell | Sep 11, 2026 | 59,379 | $10.46 |
| Tak Paul Peter | M | Sep 10, 2026 | 125,000 | $1.55 |
| Tak Paul Peter | Sell | Sep 10, 2026 | 220,866 | $11.50 |
| Tak Paul Peter | M | Sep 10, 2026 | 125,000 | - |
| Zimmermann Martine | A | Sep 8, 2026 | 64,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$38.4M | -$33.4M | -$48.3M |
| Net Income | -$37.9M | -$55.2M | -$38.2M |
| Balance Sheet | |||
| Total Assets | $41.2M | $106.9M | $125.2M |
| Equity | $12.7M | $66.3M | $51.9M |
| ROE | -297.7% | -83.2% | -73.5% |
| Per Share | |||
| EPS | $-1.31 | $-1.74 | $-0.72 |
| Cash Flow | |||
| Operating CF | - | -$27.0M | -$38.3M |
| CapEx | $457K | $16K | $587K |
Source: XBRL data in Candel Therapeutics, Inc. (CADL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CADL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $265.3M |
| Q1 2026 | 23 | $97.3M |
| Q4 2025 | 18 | $87.4M |
| Q3 2025 | 19 | $74.8M |
| Q2 2025 | 19 | $74.0M |
| Q1 2025 | 17 | $61.1M |
| Q4 2024 | 9 | $58.9M |
| Q3 2024 | 7 | $5.9M |
- State Street Corp+2.73M (+334%)
- BlackRock+1.86M (+60%)
- Bank of America Corp+231.5K (+488%)
- Vanguard Capital Management LLC+231.3K (+9%)
- Northern Trust+169.3K (+52%)
- Two Sigma Investments−60.8K (-65%)
- PNC Financial Services−64 (-42%)
- U.S. Bancorp−32 (-4%)
- D.E. Shaw & Co+108.9K
- Prudential Financial+11.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 136 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CADL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 4 | Aug 19, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CADL SEC filings: frequently asked questions
Are CADL insiders buying or selling?
In the last 90 days, Candel Therapeutics, Inc. (CADL) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $3.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CADL stock?
As of June 30, 2026, the largest Candel Therapeutics, Inc. (CADL) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($113.2 million), BlackRock ($51.2 million), State Street Corp ($36.6 million), Vanguard Capital Management LLC ($27.7 million), Millennium Management ($11.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did CADL report in its latest 8-K?
Candel Therapeutics, Inc. (CADL) filed an 8-K on September 10, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Martine Zimmermann, PharmD appointed to Candel Therapeutics’ Board of Directors.
What are the latest CADL SEC filings?
Candel Therapeutics, Inc. (CADL) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 10, 2026 and a Form 4 insider filing on October 2, 2026.
What is CADL's SEC CIK number?
Candel Therapeutics, Inc. (CADL)'s SEC Central Index Key (CIK) is 1841387. EDGAR lists every CADL filing under that number.
Ask anything about CADL
The research agent reads CADL's filings, financials, insider trades and 13F holders, then answers with sources.